A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2016-05-02

Summary

This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which should have included a platinum-based regimen.

• Phase: Phase 3

Details

• Lead Sponsor: Eisai Inc.
• Treatments: Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine